BioCentury
ARTICLE | Clinical News

Lu AA24493: Phase IIa started

November 9, 2009 8:00 AM UTC

Lundbeck began a double-blind, placebo-controlled, European Phase IIa trial to evaluate IV Lu AA24493 in 35-40 patients given for 2 weeks. The company licensed worldwide rights to Lu AA24493 for CNS-r...